Replies to post #173648 on Biotech Values

[DewDiligence]

Do we have a breakdown of [GILD’s] ION trials by GT1a vs. 1b?

GILD hasn’t disclosed the GT1a/GT1b breakdown in any of the ‘ION’ studies; they will presumably do so at the EASL conference in April. (Ditto for GILD’s disclosure of the subset data for cirrhotic patients in ION-1 and ION-2.)

…the percentage cirrhosis in the ABBV trials?

There were no cirrhotic patients in any of the ABBV/ENTA trials except TURQUOISE-2, which was 100% cirrhotics.